TOBI helps people with CF fight Pseudomonas aeruginosa in the lungs
Pseudomonas aeruginosa is the leading cause of decreasing lung function in people with CF. By taking TOBI, people with CF can help reduce the amount of Pseudomonas aeruginosa in their lungs and improve lung function.
TOBI is the only FDA-approved inhaled antibiotic that has helped people with CF fight Pseudomonas aeruginosa in the lungs for over a decade. It is approved for people aged 6 and over with a lung function within a certain range.
What TOBI could mean to you
Results from TOBI clinical studies demonstrated:
Improved lung function
Fewer days in the hospital
Less need for IV antibiotics
To find out if TOBI is right for you, talk to your doctor.
What you should know about TOBI
TOBI is approved by the FDA to treat Pseudomonas aeruginosa in the lungs of CF patients
TOBI is specifically made for inhalation
TOBI is generally safe and well tolerated
TOBI does not currently have an FDA-approved generic version
